Recovery peptides are the most widely studied and commonly used category in the research peptide space. Two compounds dominate the conversation: BPC-157 (Body Protection Compound-157) and TB500 (a synthetic fragment of Thymosin Beta-4). Both have been subjects of extensive research for their roles in tissue repair, and they work through different but complementary mechanisms.
BPC-157 is a pentadecapeptide, a chain of 15 amino acids, originally isolated from human gastric juice. Research has focused on its ability to accelerate the healing of a wide range of tissues, including tendons, ligaments, muscles, and even the gastrointestinal tract. Studies have shown it promotes angiogenesis (the formation of new blood vessels), which is critical for delivering nutrients and oxygen to damaged tissue. It's been studied in the context of tendon-to-bone healing, muscle tears, and inflammatory conditions. Common research dosing ranges from 250-500mcg per day administered subcutaneously near the injury site.
TB500 is a synthetic version of a naturally occurring 43-amino acid peptide called Thymosin Beta-4. Its primary studied mechanism involves upregulating actin, a cell-building protein that plays a crucial role in cell migration, wound healing, and the formation of new blood vessels. Research suggests TB500 promotes systemic healing, meaning its effects aren't limited to the injection site. It's commonly studied for flexibility, reduced inflammation, and accelerated recovery from muscle and connective tissue injuries. Typical research dosing is in the range of 2-5mg administered twice weekly.
The combination of BPC-157 and TB500 is one of the most popular stacks in peptide research, and for good reason. BPC-157 tends to work locally at the injury site while TB500 works systemically. Together, they address tissue repair from multiple angles, local healing, systemic inflammation reduction, blood vessel formation, and cell migration. Our Wolverine Blend combines both peptides in a single vial for convenience.
Typical recovery protocols run 4-6 weeks. Many researchers run a loading phase of higher doses for the first 2 weeks, then reduce to a maintenance dose. After the cycle, a 2-4 week break is standard before beginning another cycle if needed. Results in research settings are typically observed within the first 2-3 weeks, with continued improvement throughout the cycle.
IMPORTANT DISCLAIMER: This article is provided for educational and informational purposes only. All information is compiled from published peer-reviewed research and is intended to provide context for laboratory researchers. Nothing in this article constitutes medical, pharmaceutical, therapeutic, diagnostic, or healthcare advice of any kind. This article does not recommend, suggest, or endorse the use of any product for human or animal consumption. All products referenced are for in-vitro laboratory research only. Dosing information, protocols, cycle recommendations, and stacking suggestions referenced herein are drawn from published research studies and are provided solely as educational context for researchers. They do not constitute instructions or recommendations for human use. Purity Lab, its owners, employees, and affiliates assume no liability for any actions taken based on the information in this article. Always consult a qualified, licensed healthcare professional before making any health-related decisions. Use of any product in a manner inconsistent with its labeled research purpose is strictly prohibited and done entirely at the user's own risk.
Products mentioned in this article
Ready to start?
Take our 60-second quiz to find the right protocol for your goals.